Incyte Corp.

NASDAQ:INCY   3:59:56 PM EDT
77.42
-0.59 (-0.76%)
Products, Regulatory, Other Pre-Announcement

Eli Lilly & Incyte Provide Update On SNDA For Baricitinib For Treatment Of Moderate To Severe Atopic Dermatitis

Published: 07/16/2021 14:10 GMT
Incyte Corp. (INCY) - Lilly and Incyte Provide Update on Supplemental New Drug Application for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis.
FDA Will Not Meet Prescription Drug User Fee Act (pdufa) Action Date for Supplemental New Drug Application (snda) for Baricitinib.
Delay is Related to FDA's Ongoing Assessment of Jak Inhibitors.
Action Does Not Affect Lilly's Previously Issued Financial Guidance for 2021.